UGT1A9, UGT2B7, and MRP2 Genotypes Can Predict Mycophenolic Acid Pharmacokinetic Variability in Pediatric Kidney Transplant Recipients

被引:51
作者
Fukuda, Tsuyoshi [1 ]
Goebel, Jens [2 ]
Cox, Shareen [1 ]
Maseck, Denise [1 ]
Zhang, Kejian [3 ,4 ]
Sherbotie, Joseph R. [5 ]
Ellis, Eileen N. [6 ]
James, Laura P. [7 ,8 ]
Ward, Robert M. [9 ]
Vinks, Alexander A. [1 ]
机构
[1] Cincinnati Childrens Hosp Med Ctr, Div Clin Pharmacol, Cincinnati, OH 45229 USA
[2] Cincinnati Childrens Hosp Med Ctr, Div Nephrol & Hypertens, Cincinnati, OH 45229 USA
[3] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA
[4] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA
[5] Univ Utah, Sch Med, Div Pediat Nephrol & Hypertens, Salt Lake City, UT USA
[6] Univ Arkansas Med Sci, Dept Pediat, Arkansas Childrens Hosp, Little Rock, AR 72205 USA
[7] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA
[8] Arkansas Childrens Hosp, Sect Clin Pharmacol & Toxicol, Little Rock, AR 72202 USA
[9] Univ Utah, Sch Med, Dept Pediat, Div Neonatol, Salt Lake City, UT USA
基金
美国国家卫生研究院;
关键词
pediatric patient; mycophenolic acid; mycophenolate mofetil; pharmacogenetics; pharmacokinetics; kidney transplantation; uridine diphosphate glucuronosyltransferase; multidrug resistance-associated protein 2; SINGLE-NUCLEOTIDE POLYMORPHISMS; GLUCURONIDE METABOLITES; CLINICAL PHARMACOKINETICS; GENETIC POLYMORPHISMS; PROMOTER REGION; MOFETIL; IMPACT; IDENTIFICATION; EXPOSURE; CYCLOSPORINE;
D O I
10.1097/FTD.0b013e3182708f84
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Mycophenolic acid (MPA) exposure in pediatric patients with kidney transplant receiving body surface area (BSA)-based dosing exhibits large variability. Several genetic variants in glucuronosyltransferases (UGTs) and of multidrug resistance-associated protein 2 (MRP2) have independently been suggested to predict MPA exposure in adult patients with varying results. Here, the combined contribution of these genetic variants to MPA pharmacokinetic variability was investigated in pediatric renal transplant recipients who were on mycophenolic mofetil maintenance therapy. Methods: MPA and MPA-glucuronide concentrations from 32 patients were quantified by high-performance liquid chromatography. MPA exposure (AUC) was estimated using a 4-point abbreviated sampling strategy (predose/trough and 20 minutes, 1 hour, and 3 hours after dose) using a validated pediatric Bayesian estimator. Genotyping was performed for all of the following single nucleotide polymorphisms (SNPs): UGT1A8 830G>A(*3), UGT1A9 98T>C (*3), UGT1A9-440C>T, UGT1A9-2152C>T, UGT1A9-275T>A, UGT2B7-900A>G, and MRP2-24T>C. Results: Recipients heterozygous for MRP2-24T>C who also had UGT1A9-440C>T or UGT2B7-900A>G (n = 4), and MRP224T>C-negative recipients having both UGT1A9-440C>T and UGT2B7-900A>G (n = 5) showed a 2.2 and 1.7 times higher dose-dependent and BSA-normalized MPA-AUC compared with carriers of no or only 1 UGT-SNP (P < 0.001 and P = 0.01, respectively) (n = 7). Dose-dependent and BSA-normalized predose MPA concentrations were 3.0 and 2.4 times higher, respectively (P < 0.001). Interindividual variability in peak concentrations could be explained by the presence of the UGT1A9-440C. T genotype (P < 0.05). Conclusion: Our preliminary study demonstrates that combined UGT1A9-440C>T, UGT2B7-900A>G, and MRP2-24T>C polymorphisms can be important predictors of interindividual variability in MPA exposure in the pediatric population.
引用
收藏
页码:671 / 679
页数:9
相关论文
共 44 条
[1]   Mechanistic Basis of Using Body Size and Maturation to Predict Clearance in Humans [J].
Anderson, Brian J. ;
Holford, Nick H. G. .
DRUG METABOLISM AND PHARMACOKINETICS, 2009, 24 (01) :25-36
[2]   C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation [J].
Baldelli, Sara ;
Merlin, Simona ;
Perico, Norberto ;
Nicastri, Annalisa ;
Cortinovis, Monica ;
Gotti, Eliana ;
Remuzzi, Giuseppe ;
Cattaneo, Dario .
PHARMACOGENOMICS, 2007, 8 (09) :1127-1141
[3]   The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants [J].
Bernard, O ;
Guillemette, C .
DRUG METABOLISM AND DISPOSITION, 2004, 32 (08) :775-778
[4]   Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid [J].
Bernard, Olivier ;
Tojcic, Jelena ;
Journault, Kim ;
Perusse, Louis ;
Guillemette, Chantal .
DRUG METABOLISM AND DISPOSITION, 2006, 34 (09) :1539-1545
[5]   Increased Mycophenolic Acid Exposure in Stable Kidney Transplant Recipients on Tacrolimus as Compared With Those on Sirolimus: Implications for Pharmacokinetics [J].
Braun, F. ;
Schoecklmann, H. ;
Ziegler, E. ;
Kunzendorf, U. ;
Armstrong, V. W. ;
Renders, L. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (04) :411-415
[6]   Clinical pharmacokinetics of mycophenolate mofetil [J].
Bullingham, RES ;
Nicholls, AJ ;
Kanmm, BR .
CLINICAL PHARMACOKINETICS, 1998, 34 (06) :429-455
[7]   Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation [J].
Cattaneo, D ;
Merlini, S ;
Zenoni, S ;
Baldelli, S ;
Gotti, E ;
Remuzzi, G ;
Perico, N .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (12) :2937-2944
[8]   New solid phase extraction method for determination of mycophenolic acid and mycophenolic acid glucuronide in human plasma [J].
Cox, SL ;
Cabovska, B ;
Vinks, AA .
THERAPEUTIC DRUG MONITORING, 2005, 27 (02) :215-216
[9]   Nonlinear Relationship between Mycophenolate Mofetil Dose and Mycophenolic Acid Exposure: Implications for Therapeutic Drug Monitoring [J].
de Winter, Brenda C. M. ;
Mathot, Ron A. A. ;
Sombogaard, Ferdi ;
Vulto, Arnold G. ;
van Gelder, Teun .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 6 (03) :656-663
[10]   Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on acyl-MPAG production in vitro and in adult renal transplant patients [J].
Djebli, Nassim ;
Picard, Nicolas ;
Rerolle, Jean-Philippe ;
Le Meur, Yann ;
Marquet, Pierre .
PHARMACOGENETICS AND GENOMICS, 2007, 17 (05) :321-330